Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Pfizer Inc. named oncology chief Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten ...

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

US pharma giant Pfizer (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the ...

Pfizer has appointed Chris Boshoff, its current chief oncology officer and executive vice president, as chief scientific ...

Moderna is a good investment for the vaccine market, while Pfizer is a diversified firm trading at a discount. PFE stock is a ...

Chris Boshoff will take on the role of chief scientific officer starting Jan 1 & oversee all functions of research & ...